4 July 2018 - MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant.

Around 50-80% of adults in the UK are thought to be infected with CMV, which can remain in the body in an inactive or latent state, potentially becoming reactivated if the immune system is compromised.

As such, CMV infection is a common complication in patients taking immunosuppressants as part of a HSCT regimen, and reactivation of the virus after transplant is linked with serious complications and increased mortality.

Read Pharma Times article